Antigen Binding Molecule and Presenting Cells for Solid Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy methods, such as CAR T cell therapy, are limited in effectively treating solid tumors and require enhancement to improve their efficacy across various cancer types, including breast cancer, where cancer cells lose normal cell characteristics and spread through the body.
Innovation Solution
Administering cells with an antigen binding molecule and presenting cells expressing a solid tumor antigen that the binding molecule binds to, enhancing the capabilities and persistence of modified cells within the tumor microenvironment, thereby targeting and killing cancer cells more effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy (e.g., CAR T cell therapy) is used to treat cancer, then immune response against cancer cells is activated, but effectiveness in treating solid tumors is limited
Solution Approach 1:
The patent introduces presenting cells as an intermediary component that bridges the gap between lymphocytes and solid tumor antigens. These presenting cells express solid tumor antigens and interact with lymphocytes through antigen-binding molecules, enabling the immune system to recognize and attack solid tumors that were previously inaccessible to standard immunotherapy approaches
Solution Approach 2:
The therapy is segmented into multiple functional components: (1) modified lymphocytes with enhanced capabilities, (2) presenting cells expressing solid tumor antigens, and (3) antigen-binding molecules. This segmentation allows each component to be optimized independently and work together synergistically to overcome the limitations of treating solid tumors
2Duration of action of moving object
If cells are administered to enhance anti-tumor activity, then persistence and expansion of modified cells is improved, but complexity of the treatment protocol increases
Solution Approach 1:
Lymphocytes are pre-modified in vitro before administration to enhance their persistence and anti-tumor activity. This preliminary modification allows the cells to be optimized for long-term function in the tumor microenvironment, reducing the need for complex repeated administrations or additional in vivo interventions
Solution Approach 2:
The modified lymphocytes are engineered to self-expand and self-sustain within the tumor microenvironment through interactions with presenting cells. This self-service capability reduces the need for external support systems or complex dosing regimens, simplifying the overall treatment protocol while maintaining long persistence
Data Source
AI summary
The present disclosure relates to compositions and methods for enhancing infiltration of lymphocytes into tumor tissue, enhancing anti-tumor lymphocyte activities in tumor microenvionment (TME), inhibiting regulatory lymphocyte (e.g., B and T cells) activities in TME, and/or long term benefit of cell therapies. For example, in a method of in vivo cell expansion, the method comprises administering an effective amount of cells comprising an antigen binding molecule to a subject; and administering an effective amount of presenting cells expressing a solid tumor antigen that the binding molecule binds.